Lilly stomach cancer drug posts improved survival data; Merck touts new osteoporosis data on odanacatib; Promedior boosts D round;

Conversation on Twitter :

 @FierceBiotech: How should India regulate its clinical trial industry? More | Follow @FierceBiotech

 @JohnCFierce: Zounds! Sloan-Kettering won't use Zaltrap (Sanofi/Regeneron) based on its cost and efficacy. Influential. More | Follow @JohnCFierce

 @RyanMFierce: New website crowdsources cancer therapies (some ideas more useful than others). More | Follow @RyanMFierce

> Eli Lilly ($LLY) got a big vote of confidence from Leerink Swann today after the pharma giant boasted of positive survival results among stomach cancer patients taking ramucirumab in a Phase III study. Leerink Swann sees an 80% chance of approval for a drug that could generate up to $600 million in annual sales. Lilly didn't detail the data on survival, though. Report

> Promedior brought its D round to $24.5 million with the addition of a $3 million investment from Shire Strategic Investment Group. Story

> Merck ($MRK) touted new data on its blockbuster osteoporosis drug hopeful odanacatib, demonstrating it improved mineral density in post-menopausal women.  Story

> Lexicon Pharmaceuticals ($LXRX) saw its share price jump on Friday after reporting that its bowel disorder drug met the goals outlined in a study of gastrointestinal cancer patients.  Report

> The FDA has accepted Depomed's application for Serada, a new treatment for hot flashes. Story

Pharma News

@FiercePharma: Profile of one man who's shaking up India's patent-protected drugmakers: Cipla founder YK Hamied. More | Follow @FiercePharma

> Izvestia: Abbott engineers Russian vaccines buyout. Story

> Top U.S. hospital won't use pricey Sanofi cancer drug. Article

> Cinven builds up Mercury with Amdipharm buy. Report

Medical Device News

 @FierceMedDev: Heart stent surgeries in China are now second only to the U.S., but more than half may be unnecessary. More | Follow @FierceMedDev

 @MarkHFierce: BSX CEO explains its repositioning is an attempt, in part, to respond to a rapidly changing healthcare industry. More | Follow @MarkHFierce

 @DamianFierce: Will GSK's new transparency pledge be a boon for CROs and drug developers? More | Follow @DamianFierce

> Medtronic, St. Jude Medical pursue diversity as MN mulls same-sex marriage ban. Item

> BD, Lab21 team up for cancer diagnostics. Story

Biotech IT News

> Australia goes online for clinical trials awareness. Report

> Fight against 'unwarranted' drug patents goes online. More

> GSK to open clinical data vaults to scientists via website. Story

> Pharma group taps software to track adverse events in mobile apps. Article

CRO News

> How should India regulate its clinical trial industry? Item

> AstraZeneca taps China's Pharmaron to speed R&D. Report

> GSK's transparency pledge could be a boon to drug researchers. News

> Recipharm teams with Astimex on CDMO deal. Story

> Novasep pours $39M into new API plant. Article

And Finally… A year after having neural stem cells transplanted into the brains of four patients with a rare brain disease, investigators say they have demonstrated improved brain function after the therapy boosted levels of myelin. Story

 

Suggested Articles

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.

The delay will enable Anixa to perform additional genetic engineering intended to boost the efficacy of the treatment in ovarian cancer.